HLB Pharmaceutical Co., Ltd. (KOSDAQ:047920)
South Korea · Delayed Price · Currency is KRW 10,960
+250 (2.33%)
Jun 12, 2026, 3:30 PM KST
HLB Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 |
Net Income | 3,723 | 4,572 | 2,020 | 472.65 | -7,060 | -5,447 |
Depreciation & Amortization | 4,332 | 4,112 | 5,089 | 1,640 | 1,143 | 1,055 |
Loss (Gain) From Sale of Assets | 20.48 | -52.53 | -520.94 | 2.08 | 31.53 | 0.62 |
Asset Writedown & Restructuring Costs | 32.67 | 32.67 | 12,215 | 438.73 | - | 509.63 |
Loss (Gain) From Sale of Investments | -267.01 | -267.01 | -15,885 | -120.89 | -164.96 | 137.71 |
Loss (Gain) on Equity Investments | -2,532 | -2,324 | 1,121 | - | - | - |
Stock-Based Compensation | 102.49 | 173.44 | 288.54 | 105.02 | 431.59 | 454.54 |
Provision & Write-off of Bad Debts | -14.52 | -90.2 | 17.56 | 124.02 | 16.52 | -40.69 |
Other Operating Activities | -194.59 | -502.68 | 1,980 | 943.5 | 2,269 | 2,425 |
Change in Accounts Receivable | -3,310 | 836.54 | 2,471 | -1,990 | 1,253 | 2,198 |
Change in Inventory | -3,246 | -3,891 | -1,370 | -266.03 | -397.13 | -2,194 |
Change in Accounts Payable | 1,362 | -2,483 | 1,758 | -2,452 | 946.47 | -253.52 |
Change in Other Net Operating Assets | 2,221 | 453.15 | -2,343 | 2,456 | -246.42 | 370.51 |
Operating Cash Flow | 2,231 | 568.98 | 6,841 | 1,353 | -1,777 | -784.3 |
Operating Cash Flow Growth | -67.39% | -91.68% | 405.50% | - | - | - |
Capital Expenditures | -9,598 | -7,210 | -2,799 | -1,397 | -1,095 | -2,236 |
Sale of Property, Plant & Equipment | 114.2 | 103 | 572.95 | 4 | 24.01 | 3.4 |
Divestitures | - | - | - | - | 937.48 | - |
Sale (Purchase) of Intangibles | -2.1 | - | -292.13 | -540.15 | -280.15 | -192.6 |
Investment in Securities | 2,236 | 3,236 | -9,704 | -5,058 | 617.85 | 3,559 |
Other Investing Activities | -17,117 | -17,448 | -34 | 43.27 | 105 | 37.98 |
Investing Cash Flow | -24,368 | -21,319 | -12,256 | -6,938 | 309.09 | 1,172 |
Short-Term Debt Issued | - | - | 10,000 | 1,892 | - | 1,725 |
Long-Term Debt Issued | - | - | 903.09 | 10,914 | - | 1,400 |
Total Debt Issued | - | - | 10,903 | 12,806 | - | 3,125 |
Short-Term Debt Repaid | - | - | - | -5,546 | -371.25 | -1,400 |
Long-Term Debt Repaid | - | -1,168 | -1,045 | -1,961 | -480 | -580 |
Total Debt Repaid | -1,299 | -1,168 | -1,045 | -7,507 | -851.25 | -1,980 |
Net Debt Issued (Repaid) | -1,299 | -1,168 | 9,859 | 5,299 | -851.25 | 1,145 |
Issuance of Common Stock | 19,035 | 19,035 | 1,283 | - | - | - |
Financing Cash Flow | 17,736 | 17,867 | 11,141 | 5,299 | -851.25 | 1,145 |
Foreign Exchange Rate Adjustments | - | - | - | - | -0.35 | 3,833 |
Miscellaneous Cash Flow Adjustments | 0 | 0 | 0 | - | - | - |
Net Cash Flow | -4,401 | -2,883 | 5,726 | -286.08 | -2,320 | 5,365 |
Free Cash Flow | -7,368 | -6,642 | 4,042 | -43.8 | -2,872 | -3,020 |
Free Cash Flow Margin | -3.11% | -3.23% | 2.95% | -0.12% | -13.98% | -19.41% |
Free Cash Flow Per Share | -224.17 | -203.19 | 126.07 | -3.16 | -212.19 | -252.31 |
Cash Interest Paid | 739.62 | 740.77 | 698.18 | 288.41 | 207.01 | 274.48 |
Cash Income Tax Paid | 56.93 | 55.79 | -18.35 | 58.82 | 17.4 | 4.95 |
Levered Free Cash Flow | - | -15,677 | - | 1,808 | -540.14 | - |
Unlevered Free Cash Flow | - | -15,216 | - | 2,554 | -2.9 | - |
Change in Working Capital | -2,973 | -5,084 | 516.46 | -2,252 | 1,556 | 120.3 |